S-phase cancer associated transcript 1Genealiases: LINC02081 · XLOC_012582
Q-omics provides the consensus-scored SCAT1 profile across patient tissues and cancer cell-line models. SCAT1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SCAT1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, SCAT1 RNA expression shows 12,108 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where SCAT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCAT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCAT1 survival associations across molecular data types. SCAT1 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCAT1 RNA expression–survival associations across cancer types. High SCAT1 expression shows unfavorable associations in KIRC, ACC, OV, HNSC, UVM and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SCAT1 RNA expression.
This table summarizes SCAT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SCAT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCAT1 shows higher tumor expression in HNSC, KIRC, COAD, LUAD, BLCA and STAD. The HNSC box plot shows higher SCAT1 RNA expression in tumor versus normal tissue (log2 FC = +2.748, t-test p < 0.001).
This table shows molecular features associated with SCAT1 in patient tissues and cancer cell lines. In patient samples, SCAT1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
